United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Amgen

Bristol-Myers

Johnson & Johnson

Eli Lilly

Novartis

All the drugmakers that make the 10 prescription medicines subject to the first-ever price negotiations for the U.S. Medicare health program, including Amgen and Novartis , said they signed on to participate in the talks by the Oct. 1 deadline.

Drugmakers sign on to negotiate Medicare prices under protest

AstraZeneca

Merck

Novo Nordisk

A federal judge dealt a blow to hopes for a near-term injunction to halt the federal government plan to let Medicare to pay less for a few expensive medicines.

Big Pharma Can't Stop the Price-Negotiation Program. What's Next.

With a few exceptions, pharmaceutical stocks have underperformed the broader market this year. The S&P Pharmaceutical Index is down 3% year to date versus a 12% gain in the benchmark S&P 500.

Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024

UnitedHealth Group

UnitedHealth is showing no signs of slowing down. Pfizer's sell-off has gone too far.

3 Top Stocks to Buy in October and Hold Forever

BioNTech SE

While people in this country aren't rushing in masses to get updated COVID booster vaccines, take-up has been encouraging. Many are worried about an apparent resurgence in the affliction.

Why Pfizer and BioNTech Stocks Zoomed Higher Today

The market for obesity and weight management drugs is attracting a lot of interest lately in the United States. Patients are gradually understanding the benefits of obesity drugs like Novo Nordisk's NVO Wegovy.

3 Stocks to Focus on as Demand for Obesity Drugs Booms

Amazon

Chipotle

Dollar General

T-Mobile US

Analyst ratings are not perfect, but they're one of the better ways for investors to forecast future stock price movement. Here are five stocks that analysts believe have massive upside for patient, long-term investors.

5 Stocks That Have Massive Upside According to Analysts

Extra Space Storage

Take-Two Interactive Software

We are in what is historically considered the slow season of the investing world, but there are still opportunities for value-minded investors willing to turn over a rock or two. Here are three undervalued stocks to consider.

3 Top Undervalued Stocks To Watch: October 2023

Its business is slowing because COVID-19 revenue has fallen drastically this year. The company is also facing the loss of patent protection on multiple drugs.

Where Will Pfizer Be in 5 Years?

Moderna

Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.

Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?

In the ever-evolving world of the stock market, uncovering potential gold mines is paramount for smart investing. One promising area to consider is undervalued biotech stocks.

Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Resilience

We assess the key factors driving the persistent decline in the share price of Pfizer, one of the world's leading biopharmaceutical companies. We think the stock deserves to trade at a much higher P/E multiple of 20x or more, given its healthy pipeline and industry-leading R&D capabilities. Based on our conservative annualized EPS target of $2.68 and a 20x P/E multiple, we expect Pfizer's shares to outperform in the next 12 to 18 months.

Pfizer: Sell-Off Overdone, Healthy Pipeline To Sustain Above 15% ROE

Advanced Micro Devices

Broadcom

American Express

NIKE

Taiwan Semiconductor Manufacturing

Walmart

Blue-chip stocks are shares of well-established, stable firms that pay dividends in most cases. It's that combination of stability and dividend income that makes them so attractive.

Smart Picks: 7 Blue-Chips Trading Below True Value

CRISPR Therapeutics

The pharmaceuticals market has taken a bit of a breather in recent weeks after an exhilarating rally earlier this year. But seasoned investors know the ups and downs are part of the natural ebb and flow of the market, and that patience and discipline are rewarded in the long-run.

Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher

Ginkgo Bioworks Holdings

Ginkgo Bioworks (NYSE: DNA ) stock jumped almost 14% overnight after it signed a collaboration agreement with Pfizer (NYSE: PFE ). The deal gives Ginkgo upfront cash and could eventually be worth $331 million, based on its RNA technology.

DNA Stock Alert: Ginkgo Bioworks Announces Major Partnership With Pfizer

Shares of Ginkgo Bioworks Holdinsg Inc jumped 16% premarket following the announcement of a potentially lucrative tie-up with pharmaceutical giant Pfizer Inc (NYSE:PFE). The partnership aims to leverage Ginkgo's cutting-edge RNA technology to discover and develop novel RNA molecules for "priority research areas".

Ginkgo Bioworks up 16% premarket on the back of $331m Pfizer deal

BOSTON , Sept. 27, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with Pfizer (NYSE: PFE) focused on the discovery of RNA-based drug candidates.

Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer

Pfizer Inc. (NYSE:PFE ) Cantor Fitzgerald Annual Global Health Conference Call September 26, 2023 3:30 PM ET Company Participants Albert Bourla - Chairman & CEO Conference Call Participants Louise Chen - Cantor Fitzgerald Louise Chen All right. Good day, everybody.

Pfizer Inc. (PFE) Cantor Fitzgerald Annual Global Health Conference (Transcript)

Pfizer Inc's chief executive said on Tuesday that almost 250,000 courses of the drugmaker's oral antiviral COVID-19 treatment Paxlovid were being administered per week as cases surged in the United States.

About 250,000 courses of COVID pill Paxlovid being administered per week - Pfizer CEO

Pfizer Inc. said late Monday that it has restarted production at a North Carolina facility badly damaged by a tornado in July, but warned that some medications will not be in “full supply” until next year.

Pfizer restarts production at tornado-damaged facility, but some supply is still affected

Pfizer expects operations to fully resume by the end of the year, but it warned that supply of some medicines would be affected until at least mid-2024.

Pfizer restarts production at tornado-hit North Carolina plant, but drug supply will still be affected

Pfizer said on Monday it has restarted majority of the production lines at its tornado-hit North Carolina plant, but warned that supply of some drugs from the facility may not be fully restored until at least the middle of next year.

Pfizer restarts production at tornado-hit North Carolina plant

Pfizer's (PFE) Abrysvo has been recommended by the CDC for preventing RSV in infants by immunizing pregnant women, during weeks 32-36 of pregnancy.

CDC Recommends Pfizer's (PFE) RSV Jab to Protect Newborns

Pfizer's revenues were declining prior to the pandemic, but the success of its COVID vaccine and antiviral brought in unexpected additional revenues of >$55bn over 2 years. The company has been on a major M&A spending spree, investing approximately $27bn in under 2 years, with a potential total spending of $70bn. Pfizer aims to drive $45bn in new product revenue by 2030 through its in-house pipeline and business development, with a projected CAGR of 6%.

Pfizer: Protracted Selloff Makes This Best Time To Buy For A Decade

RSV is one of the leading causes of hospitalizations among infants in the U.S., according to the CDC.

News for Pfizer Stock (PFE)